CALCA and migraine disorder: Two studies documented an improvement after switching to another anti-CGRP-mAb; 8/25 [62] and 8/15 [65] patients showed a ≥30% improvement in monthly migraine days after switching from anti-receptor-mAb to an anti-ligand-mAb.